DOCSLIB.ORG

Gallamine Triethiodide

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Gallamine Triethiodide 1906 Neuromuscular Blockers years of age at an initial rate equivalent to cisatracuri- tion in general anaesthesia for surgical procedures and to aid con- mine undue sensitivity. In the UK, initial doses of 80 to 120 mg um 3 micrograms/kg per minute followed by a rate of trolled ventilation. Doxacurium has little histamine-releasing ac- by intravenous injection have been recommended, with further tivity and causes negligible vagal or sympathetic blockade so doses of 20 to 40 mg as required. In children, a dose of 1.5 mg/kg 1 to 2 micrograms/kg per minute after stabilisation. that significant cardiovascular adverse effects are not a problem. has been recommended, reduced to 600 micrograms/kg for ne- ◊ Reviews. Preparations onates. 1. Bryson HM, Faulds D. Cisatracurium besilate: a review of its In some other countries lower doses have generally been used; an pharmacology and clinical potential in anaesthetic practice. Proprietary Preparations (details are given in Part 3) initial dose of 1 mg/kg intravenously, up to a maximum of Drugs 1997; 53: 848–66. Canad.: Nuromax†; USA: Nuromax†. 80 mg, with additional doses of 0.5 to 1 mg/kg after about 50 to Administration in infants and children. Children generally 60 minutes if required. require larger doses of competitive neuromuscular blockers on a Gallamine triethiodide has also been given intramuscularly, with weight basis than adolescents or adults to achieve similar degrees Gallamine Triethiodide (BANM, rINN) or without hyaluronidase. of neuromuscular blockade and may recover more quickly. In Benzcurine Iodide; Galamin Trietiyodür; Galamino trietjodidas; Preparations contrast, neonates and infants under 1 year of age are more sen- Gallamiinitrietjodidi; Gallamine, triéthiodure de; Gallamini triethi- BP 2008: Gallamine Injection; sitive and usual doses may produce prolonged neuromuscular USP 31: Gallamine Triethiodide Injection. blockade (see also above for some suggested doses). odidum; Gallamin-triethojodid; Gallamintrietjodid; Gallamin-tri- etjodid; Gallamone Triethiodide; Trietioduro de galamina. 2,2′,2″- Proprietary Preparations (details are given in Part 3) References. UK: Flaxedil†. 1. Brandom BW, Fine GF. Neuromuscular blocking drugs in pedi- (Benzene-1,2,3-triyltrioxy)tris(tetraethylammonium) tri-iodide. atric anesthesia. Anesthesiol Clin North America 2002; 20: Галламина Триэтйодид 45–58. C30H60I3N3O3 = 891.5. ECT. Competitive neuromuscular blockers have been used to re- CAS — 153-76-4 (gallamine); 65-29-2 (gallamine triethi- Metocurine Iodide (USAN) duce the intensity of muscle contractions and minimise trauma in odide). Dimethyl Tubocurarine Iodide; (+)-O,O′-Dimethylchondrocurar- patients receiving ECT, but suxamethonium (p.1912) is general- ATC — M03AC02. ine Di-iodide; Dimethyltubocurarine Iodide; Dimetiltubocurarin- ly preferred because of its short duration of action. ATC Vet — QM03AC02. io, ioduro de; Metocurini Iodidum; Metokuriinijodidi; Metokurin- Intravenous regional anaesthesia. Competitive neuromus- jodid; Trimethyltubocurarine Iodide. (+)-6,6′,7′,12′-Tetrameth- cular blockers and/or opioid analgesics have been added to the oxy-2,2,2′,2′-tetramethyltubocuraranium di-iodide. local anaesthetic used in intravenous regional anaesthesia CH 3 CH3 C40H48I2N2O6 = 906.6. (p.1853) to improve the quality of anaesthesia. However atracu- CAS — 5152-30-7 (metocurine); 7601-55-0 (metocurine rium (see Tourniquets under Precautions, above) and mivacuri- N CH3 iodide). um (see Tourniquets, p.1907) might be unsuitable for such use. O ATC — M03AA04. 3 I Shivering. Various drugs have been tried in the treatment of O O ATC Vet — QM03AA04. postoperative shivering (p.1779). There are reports of neuromus- H3C N N CH3 cular blockers being used to treat shivering after cardiac surgery in order to reduce cardiovascular stress;1 one study2 has suggest- H C CH 3 H3C CH3 3 H3C CH3 O OCH3 ed that vecuronium might be preferable to pancuronium as it + does not increase myocardial work and may be associated with N OCH3 fewer complications. Pharmacopoeias. In Eur. (see p.vii), Int., and US. 1. Cruise C, et al. Comparison of meperidine and pancuronium for Ph. Eur. 6.2 (Gallamine Triethiodide). A white, or almost white, H − 2 l the treatment of shivering after cardiac surgery. Can J Anaesth hygroscopic powder. Very soluble in water; slightly soluble in al- H 1992; 39: 563–8. cohol; practically insoluble in dichloromethane. Store in airtight + 2. Dupuis J-Y, et al. Pancuronium or vecuronium for the treatment containers. Protect from light. O N of shivering after cardiac surgery. Anesth Analg 1994; 79: USP 31 (Gallamine Triethiodide). A white, hygroscopic, odour- 472–81. H3CO OCH3 less, amorphous powder. Very soluble in water; sparingly soluble H3C CH3 Tetanus. For a comment on the role of competitive neuromus- in alcohol; very slightly soluble in chloroform. pH of a 2% solu- cular blockers in the management of muscle spasms caused by tion in water is between 5.3 and 7.0. Store in airtight containers. tetanus, see p.1901. Protect from light. Profile Metocurine iodide is a benzylisoquinolinium competitive neu- Preparations Adverse Effects, Treatment, and Precautions romuscular blocker (see Atracurium, p.1905) that has been used USP 31: Atracurium Besylate Injection. As for competitive neuromuscular blockers in general (see Atra- to provide muscle relaxation in surgical and other procedures. Proprietary Preparations (details are given in Part 3) curium, p.1902). Tachycardia often develops due to the vagolytic Metocurine iodide has a moderate risk of inducing histamine re- Arg.: Gelolagar; Nimbex†; Nimbium; Tracrium; Tracurix; Tracuron; Aus- action of gallamine triethiodide and blood pressure may be lease; it also has some ganglion blocking activity. tral.: Nimbex; Tracrium; Austria: Nimbex; Tracrium; Belg.: Nimbex; raised. It has a small histamine-releasing effect; occasional ana- Tr acr ium; Braz.: Abbottracurium; Nimbium; Sitrac†; Tracrium; Tracur; Ca- phylactoid reactions have been reported. It should be avoided in nad.: Nimbex; Chile: Nimbex; Tracrium; Cz.: Nimbex; Tracrium; Denm.: patients hypersensitive to iodine and in severe renal impairment. Nimbex; Tracrium†; Fin.: Nimbex; Fr.: Nimbex; Tracrium; Ger.: Nimbex; Although competitive muscle relaxants have been given with Tr acr ium; Gr.: Nimbex; Tracrium; Hong Kong: Nimbex; Tracrium; Hung.: Mivacurium Chloride (BAN, USAN, rINN) Nimbex; Tracrium; India: Tracrium; Indon.: Notrixum; Tracrium; Tramus; great care to patients with myasthenia gravis (see Neuromuscular Irl.: Nimbex; Tracrium; Israel: Mycurium; Tracrium; Ital.: Acurmil; Nimbex; Disorders, p.1903), UK licensed product information for BW-B1090U; Cloruro de mivacurio; Mivacurii Chloridum; Miva- Tr acr ium; Malaysia: Nimbex; Tracrium; Mex.: Ifacur†; Nimbex; Relatrac; gallamine triethiodide recommended that it should not be used in curium, Chlorure de; Mivakuriumklorid; Mivakuriumkloridi; Mi- Trablok; Tracrium; Neth.: Nimbex; Tracrium; Norw.: Nimbex; NZ: Tr acr i- such patients. vakuryum Klorür. A mixture of the stereoisomers of (E)- um; Philipp.: Tracrium; Pol.: Abbocurium; Nimbex; Tracrium; Port.: Faulcurium; Nimbex; Tracrium; Rus.: Nimbex (Нимбекс); Tracrium Cardiopulmonary bypass. Alterations in the pharmacokinet- 1,1′,2,2′,3,3′,4,4′-octahydro-6,6′,7,7′-tetramethoxy-2,2′-dimethyl- (Тракриум); S.Afr.: Nimbex; Tracrium; Singapore: Nimbex†; Tracrium; ics of competitive neuromuscular blockers in patients undergo- 1,1′-bis(3,4,5-trimethoxybenzyl)-2,2′-[oct-4-enedioylbis(oxytri- Spain: Laurak; Nimbex; Tracrium; Swed.: Nimbex; Tracrium; Switz.: Nim- ing surgery involving cardiopulmonary bypass usually necessi- methylene)]di-isoquinolinium dichloride. bex; Tracrium; Thai.: Nimbex; Tracrium; Turk.: Dematrac; Nimbex; Tracri- tate the use of reduced doses (see p.1903). However, the um; UK: Nimbex; Tracrium; USA: Nimbex; Tracrium. pharmacokinetics of gallamine in patients undergoing cardiopul- Мивакурия Хлорид monary bypass appear not to differ significantly from those in C58H80Cl2N2O14 = 1100.2. control patients.1 CAS — 106861-44-3 (mivacurium chloride, total race- Doxacurium Chloride (BAN, USAN, rINN) 1. Shanks CA, et al. Gallamine disposition in open-heart surgery mate). involving cardiopulmonary bypass. Clin Pharmacol Ther 1983; ATC — M03AC10. BW-A938U; Cloruro de doxacurio; Doksakuriumkloridi; Doxa- 33: 792–9. curii Chloridum; Doxacurium, Chlorure de; Doxakuriumklorid. ATC Vet — QM03AC10. Renal impairment. Gallamine triethiodide is excreted A mixture of the (1R,1′S,2S,2′R), (1R,1′R,2S,2′S), and (1S,1′S,2R,2′R) unchanged in the urine and UK licensed product information stereoisomers (a meso isomer and two enantiomers respect- considered that it should be avoided in severe renal impairment ively) of 1,1′,2,2′,3,3′,4,4′-octahydro-6,6′,7,7′,8,8′-hexamethoxy- since prolonged paralysis may occur. Significantly prolonged 2,2′-dimethyl-1,1′-bis(3,4,5-trimethoxybenzyl)-2,2′-[butanedioyl- elimination half-life and reduced clearance have been reported1 bis(oxytrimethylene)]di-isoquinolinium dichloride, all of which in patients with chronic renal failure given gallamine triethiodide are in a trans configuration at the 1 and 2 positions of the isoqui- in initial doses of 2 mg/kg intravenously. nolinium rings. 1. Ramzan MI, et al. Gallamine disposition in surgical patients with chronic renal failure. Br J Clin Pharmacol 1981; 12: 141–7. Доксакурия Хлорид C H Cl N O = 1106.1. Interactions 56 78 2 2 16 For interactions associated with competitive neuromuscular Incompatibility. See under Atracurium, p.1902
Load more

Recommended publications
  • Anaesthetic Experience with Paediatric Interventional Cardiology
    320 Occasional Survey Anaesthetic experience with paediatric inter- Shobha Malviya MD, Frederick A. Burrows MD FRCPC, Albert E. Johnston MD FRCPC, Lee N. Benson MD FRCPC ventional cardiology Anaesthetic and sedation techniques, complications and out- In recent years interventional cardiologic procedures have comes were reviewed in 176 children undergoing 184 interven- replaced thoracic and cardiac surgery in the treatment of tional cardiologic procedures. Techniques included sedation certain cardiac anomalies in children. Balloon dilatation only, and ketamine, inhalational or narcotic anaesthesia. is particularly effective in treating pulmonary valve Ketamine infusion was the technique most frequently used. stenosis and is also performed as a nonsurgical alternative Ketamine was associated with a higher incidence of respiratory for patients with aortic valve stenosis, recoaretation of the complications (P < 0.05) than the other techniques. The higher aorta and pulmonary artery stenosis. Insertion of an incidence of hypercarbia (15.6 per cent), which did not affect occlusion device is used to treat patent ductus arteriosus. outcome, may be attributable to the use of supplemental Procedures performed in the cardiac catheterisation sedatives. The incidence of upper airway obstruction (7.8 per suite require a darkened room, allow poor access to the cenO was similar to that of previous studies. Vascular compro- often critically ill patient and present the potential for mise resulted from the procedure in 33 patients, necessitating sudden devastating complications, including rupture of a surgical correction in 16. Cardiac perforation occurred in four cardiac chamber. In addition, interventional procedures cases, causing one death. Pulmonary valve stenosis was most require a steady haemodynamic state before oxygen amenable to balloon dilatation and aortic valve stenosis least saturation and pressures in the various cardiac chambers amenable.
    [Show full text]
  • Muscle Relaxants Physiologic and Pharmacologic Aspects
    K. Fukushima • R. Ochiai (Eds.) Muscle Relaxants Physiologic and Pharmacologic Aspects With 125 Figures Springer Contents Preface V List of Contributors XVII 1. History of Muscle Relaxants Some Early Approaches to Relaxation in the United Kingdom J.P. Payne 3 The Final Steps Leading to the Anesthetic Use of Muscle Relaxants F.F. Foldes 8 History of Muscle Relaxants in Japan K. Iwatsuki 13 2. The Neuromuscular Junctions - Update Mechanisms of Action of Reversal Agents W.C. Bowman 19 Nicotinic Receptors F.G. Standaert 31 The Neuromuscular Junction—Basic Receptor Pharmacology J.A. Jeevendra Martyn 37 Muscle Contraction and Calcium Ion M. Endo 48 3. Current Basic Experimental Works Related to Neuromuscular Blockade in Present and Future Prejunctional Actions of Neuromuscular Blocking Drugs I.G. Marshall, C. Prior, J. Dempster, and L. Tian 51 VII VIII Approaches to Short-Acting Neuromuscular Blocking Agents J.B. Stenlake 62 Effects Other than Relaxation of Non-Depolarizing Muscle Relaxants E.S. Vizi 67 Regulation of Innervation-Related Properties of Cultured Skeletal Muscle Cells by Transmitter and Co-Transmitters R.H. Henning 82 4. Current Clinical Experimental Works Related to Neuromuscular Blockade in Present and Future Where Should Experimental Works Be Conducted? R.D. Miller 93 Muscle Relaxants in the Intensive Care Unit ! J.E. Caldwell 95 New Relaxants in the Operating Room R.K. Mirakhur 105 Kinetic-Dynamic Modelling of Neuromuscular Blockade C. Shanks Ill 5. Basic Aspects of Neuromuscular Junction Physiology of the Neuromuscular Junction W.C. Bowman 117 Properties of <x7-Containing Acetylcholine Receptors and Their Expression in Both Neurons and Muscle D.K.
    [Show full text]
  • Product Monograph Vecuronium Bromide For
    PRODUCT MONOGRAPH PrVECURONIUM BROMIDE FOR INJECTION Non-depolarizing Skeletal Neuromuscular Blocking Agent Pharmaceutical Partners of Canada Inc. Date of Preparation: 45 Vogell Road, Suite 200 January 15, 2008 Richmond Hill, ON L4B 3P6 Control No.: 119276 PRODUCT MONOGRAPH PrVECURONIUM BROMIDE FOR INJECTION Non-depolarizing Skeletal Neuromuscular Blocking Agent THIS DRUG SHOULD BE ADMINISTERED ONLY BY ADEQUATELY TRAINED INDIVIDUALS FAMILIAR WITH ITS ACTIONS, CHARACTERISTICS AND HAZARDS ACTIONS AND CLINICAL PHARMACOLOGY Vecuronium Bromide for Injection is a non-depolarizing neuromuscular blocking agent of intermediate duration possessing all of the characteristic pharmacological actions of this class of drugs (curariform). It acts by competing for cholinergic receptors at the motor end-plate. The antagonism to acetylcholine is inhibited and neuromuscular block reversed by acetylcholinesterase inhibitors such as neostigmine. Vecuronium Bromide for Injection is about 1/3 more potent than pancuronium; the duration of neuromuscular blockade produced by Vecuronium Bromide for Injection is shorter than that of pancuronium at initially equipotent doses. The time to onset of paralysis decreases and the duration of maximum effect increases with increasing Vecuronium Bromide for Injection doses. The use of a peripheral nerve stimulator is of benefit in assessing the degree of muscular relaxation. The ED90 (dose required to produce 90% suppression of the muscle twitch response with balanced anesthesia) has averaged 0.057 mg/kg (0.049 to 0.062 mg/kg in various studies). An initial Vecuronium Bromide for Injection dose of 0.08 to 0.10 mg/kg generally produces first depression of twitch in approximately 1 minute, good or excellent intubation conditions within 2.5 to 3 minutes, and maximum neuromuscular blockade within 3 to 5 minutes of injection in Vecuronium Bromide for Injection, Product Monograph Page 2 of 28 most patients.
    [Show full text]
  • BRS Pharmacology
    Pharmacology Gary C. Rosenfeld, Ph.D. Professor Department of Integrated Biology and Pharmacology and Graduate School of Biomedical Sciences Assistant Dean for Education Programs University of Texas Medical School at Houston Houston, Texas David S. Loose, Ph.D. Associate Professor Department of Integrated Biology and Pharmacology and Graduate School of Biomedical Sciences University of Texas Medical School at Houston Houston, Texas With special contributions by Medina Kushen, M.D. William Beaumont Hospital Royal Oak, Michigan Todd A. Swanson, M.D., Ph.D. William Beaumont Hospital Royal Oak, Michigan Acquisitions Editor: Charles W. Mitchell Product Manager: Stacey L. Sebring Marketing Manager: Jennifer Kuklinski Production Editor: Paula Williams Copyright C 2010 Lippincott Williams & Wilkins 351 West Camden Street Baltimore, Maryland 21201-2436 USA 530 Walnut Street Philadelphia, PA 19106 All rights reserved. This book is protected by copyright. No part of this book may be reproduced in any form or by any means, including photocopying, or utilized by any information storage and retrieval system without written permission from the copyright owner. The publisher is not responsible (as a matter of product liability, negligence or otherwise) for any injury resulting from any material contained herein. This publication contains information relating to general principles of medical care which should not be construed as specific instructions for individual patients. Manufacturers’ product information and package inserts should be reviewed for current information, including contraindications, dosages and precautions. Printed in the United States of America Library of Congress Cataloging-in-Publication Data Rosenfeld, Gary C. Pharmacology / Gary C. Rosenfeld, David S. Loose ; with special contributions by Medina Kushen, Todd A.
    [Show full text]
  • Doxacurium Chloride Injection Abbott Laboratories
    NUROMAX - doxacurium chloride injection Abbott Laboratories ---------- NUROMAX® (doxacurium chloride) Injection This drug should be administered only by adequately trained individuals familiar with its actions, characteristics, and hazards. NOT FOR USE IN NEONATES CONTAINS BENZYL ALCOHOL DESCRIPTION NUROMAX (doxacurium chloride) is a long-acting, nondepolarizing skeletal muscle relaxant for intravenous administration. Doxacurium chloride is [1α,2β(1'S*,2'R*)]-2,2' -[(1,4-dioxo-1,4- butanediyl)bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7,8-trimethoxy-2- methyl-1-[(3,4,5- trimethoxyphenyl)methyl]isoquinolinium] dichloride (meso form). The molecular formula is C56H78CI2N2O16 and the molecular weight is 1106.14. The compound does not partition into the 1- octanol phase of a distilled water/ 1-octanol system, i.e., the n-octanol:water partition coefficient is 0. Doxacurium chloride is a mixture of three trans, trans stereoisomers, a dl pair [(1R,1'R ,2S,2'S ) and (1S,1'S ,2R,2'R )] and a meso form (1R,1'S,2S,2'R). The meso form is illustrated below: NUROMAX Injection is a sterile, nonpyrogenic aqueous solution (pH 3.9 to 5.0) containing doxacurium chloride equivalent to 1 mg/mL doxacurium in Water for Injection. Hydrochloric acid may have been added to adjust pH. NUROMAX Injection contains 0.9% w/v benzyl alcohol. Reference ID: 2867706 CLINICAL PHARMACOLOGY NUROMAX binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine. Pharmacodynamics NUROMAX is approximately 2.5 to 3 times more potent than pancuronium and 10 to 12 times more potent than metocurine.
    [Show full text]
  • Atracurium Besylate Injection
    PRODUCT MONOGRAPH PrATRACURIUM BESYLATE INJECTION 10 mg/mL Skeletal Neuromuscular Blocking Agent Sandoz Canada Inc. Date of Revision: March 25, 2013 145 Jules-Léger Boucherville, QC, Canada J4B 7K8 Control no.: 161881 Atracurium Besylate Injection Page 1 of 19 PrATRACURIUM BESYLATE INJECTION 10 mg/mL THERAPEUTIC CLASSIFICATION Skeletal Neuromuscular Blocking Agent ACTIONS AND CLINICAL PHARMACOLOGY Atracurium besylate is a nondepolarizing, intermediate-duration, skeletal neuromuscular blocking agent. Nondepolarizing agents antagonize the neurotransmitter action of acetylcholine by binding competitively to cholinergic receptor sites on the motor end-plate. This antagonism is inhibited, and neuromuscular block reversed, by acetylcholinesterase inhibitors such as neostigmine, edrophonium and pyridostigmine. The duration of neuromuscular blockade produced by atracurium besylate is approximately one-third to one-half the duration seen with d-tubocurarine, metocurine and pancuronium at equipotent doses. As with other nondepolarizing neuromuscular blockers, the time to onset of paralysis decreases and the duration of maximum effect increases with increasing atracurium besylate doses. The pharmacokinetics of atracurium besylate in man are essentially linear within the 0.3 to 0.6 mg/kg dose range. The elimination half-life is approximately 20 minutes. The duration of neuromuscular blockade does not correlate with plasma pseudocholinesterase levels and is not altered by the absence of renal function. INDICATIONS AND CLINICAL USE Atracurium Besylate Injection is indicated, as an adjunct to general anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. It can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored. CONTRAINDICATIONS Atracurium besylate is contraindicated in patients known to have a hypersensitivity to it.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/009874.6 A1 King (43) Pub
    US 201000987.46A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/009874.6 A1 King (43) Pub. Date: Apr. 22, 2010 (54) COMPOSITIONS AND METHODS FOR Related U.S. Application Data TREATING PERIODONTAL DISEASE COMPRISING CLONDINE, SULINDAC (60) Provisional application No. 61/106,815, filed on Oct. AND/OR FLUOCNOLONE 20, 2008. Publication Classification (75) Inventor: Vanja Margareta King, Memphis, TN (US) (51) Int. Cl. A6F I3/00 (2006.01) Correspondence Address: A6II 3/56 (2006.01) MEDTRONIC (52) U.S. Cl. ......................................... 424/435: 514/171 Attn: Noreen Johnson - IP Legal Department (57) ABSTRACT 2600 Sofamor Danek Drive MEMPHIS, TN38132 (US) Effective treatments of periodontal disease for extended peri ods of time are provided. Through the administration of an (73) Assignee: Warsaw Orthopedic, Inc., Warsaw, effective amount of clonidine, Sulindac, and/or fluocinolone IN (US) at or near a target site, one can reduce, prevent, and/or treat periodontal disease. In some embodiments, when appropriate (21) Appl. No.: 12/572,387 formulations are provided within biodegradable polymers, treatment can be continued for at least two weeks to two (22) Filed: Oct. 2, 2009 months. Patent Application Publication Apr. 22, 2010 Sheet 1 of 3 US 2010/009874.6 A1 FIG. 1 Clonidine 15 o 9. 10 wd O O 2 SS 5 O RANK Control 100 M 10 M M 0.1 LM Concentration Patent Application Publication Apr. 22, 2010 Sheet 2 of 3 US 2010/009874.6 A1 FIG. 2 Sulindac 5 1 O RANK Control 70 M 35M 7.5 M ConCentration Patent Application Publication Apr.
    [Show full text]
  • S1 Table. List of Medications Analyzed in Present Study Drug
    S1 Table. List of medications analyzed in present study Drug class Drugs Propofol, ketamine, etomidate, Barbiturate (1) (thiopental) Benzodiazepines (28) (midazolam, lorazepam, clonazepam, diazepam, chlordiazepoxide, oxazepam, potassium Sedatives clorazepate, bromazepam, clobazam, alprazolam, pinazepam, (32 drugs) nordazepam, fludiazepam, ethyl loflazepate, etizolam, clotiazepam, tofisopam, flurazepam, flunitrazepam, estazolam, triazolam, lormetazepam, temazepam, brotizolam, quazepam, loprazolam, zopiclone, zolpidem) Fentanyl, alfentanil, sufentanil, remifentanil, morphine, Opioid analgesics hydromorphone, nicomorphine, oxycodone, tramadol, (10 drugs) pethidine Acetaminophen, Non-steroidal anti-inflammatory drugs (36) (celecoxib, polmacoxib, etoricoxib, nimesulide, aceclofenac, acemetacin, amfenac, cinnoxicam, dexibuprofen, diclofenac, emorfazone, Non-opioid analgesics etodolac, fenoprofen, flufenamic acid, flurbiprofen, ibuprofen, (44 drugs) ketoprofen, ketorolac, lornoxicam, loxoprofen, mefenamiate, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, pranoprofen, proglumetacin, sulindac, talniflumate, tenoxicam, tiaprofenic acid, zaltoprofen, morniflumate, pelubiprofen, indomethacin), Anticonvulsants (7) (gabapentin, pregabalin, lamotrigine, levetiracetam, carbamazepine, valproic acid, lacosamide) Vecuronium, rocuronium bromide, cisatracurium, atracurium, Neuromuscular hexafluronium, pipecuronium bromide, doxacurium chloride, blocking agents fazadinium bromide, mivacurium chloride, (12 drugs) pancuronium, gallamine, succinylcholine
    [Show full text]
  • COMPARISON of ROCURONIUM BROMIDE and SUCCINYLCHOLINE CHLORIDE for USE DURING RAPID SEQUENCE INTUBATION in ADULTS Ch
    DOI: 10.18410/jebmh/2015/672 ORIGINAL ARTICLE COMPARISON OF ROCURONIUM BROMIDE AND SUCCINYLCHOLINE CHLORIDE FOR USE DURING RAPID SEQUENCE INTUBATION IN ADULTS Ch. Penchalaiah1, N. Jagadeesh Babu2, T. Kumar3 HOW TO CITE THIS ARTICLE: Ch. Penchalaiah, N. Jagadeesh Babu, T. Kumar. ”Comparison of Rocuronium Bromide and Succinylcholine Chloride for Use during Rapid Sequence Intubation in Adults”. Journal of Evidence based Medicine and Healthcare; Volume 2, Issue 32, August 10, 2015; Page: 4796-4806, DOI: 10.18410/jebmh/2015/672 ABSTRACT: BACKGROUND AND OBJECTIVE: The goal of rapid sequence intubation is to secure the patients airway smoothly and quickly, minimizing the chances of regurgitation and aspiration of gastric contents. Traditionally succinylcholine chloride has been the neuromuscular blocking drug of choice for use in rapid sequence intubation because of its rapid onset of action and profound relaxation. Succinylcholine chloride remains unsurpassed in providing ideal intubating conditions. However the use of succinylcholine chloride is associated with many side effects like muscle pain, bradycardia, hyperkalaemia and rise in intragastric and intraocular pressure. Rocuronium bromide is the only drug currently available which has the rapidity of onset of action like succinylcholine chloride. Hence the present study was undertaken to compare rocuronium bromide with succinylcholine chloride for use during rapid sequence intubation in adult patients. METHODOLOGY: The study population consisted of 90 patients aged between 18-60 years posted for various elective surgeries requiring general anaesthesia. Study population was randomly divided into 3 groups with 30 patients in each sub group. 1. Group I: Intubated with 1 mg kg-1 of succinylcholine chloride (n=30).
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Overall Educational Goal of Elective the Goal of This Rotation Is to Enable
    Overall Educational Goal of Elective The goal of this rotation is to enable students to better understand the risks and hazards of anesthesia, so that they can learn to safely prepare a patient physically and emotionally for the operating room. Students will also become familiar with problems specific to anesthesia, so that they will be able to consult with the anesthesiologist regarding medical problems that may affect the patient’s response to anesthesia and surgery. In the process, students will learn what it means for a patient to be in the most optimal condition before proceeding to the operating room. Objectives • To give students an appreciation of the field of Anesthesiology • To teach techniques of preoperative evaluation and the implications of concurrent medical conditions in the intraoperative period • To teach the characteristics of commonly used anesthetic agents and techniques and their risks and complications • To acquaint students with the principles and skills involved in airway management, intravenous line insertion, and the use of invasive and non-invasive monitoring Brief Description of Activities Students will participate in the induction of anesthesia and the maintenance of an airway by both mask and intubation; intraoperative management including the use of various anesthetic agents; various regional anesthetic techniques; pain management for acute and chronic conditions; the anesthetic management of the obstetrical, cardiac and pediatric patient; and anesthetic goals in an ambulatory setting. Methods of Student Evaluation Students will be assigned to an anesthesia attending and resident who will be responsible for evaluating their progress. Evaluation will be done by observing the students involvement in the intraoperative management of the patients that they are following and their ability to handle simple anesthetic techniques.
    [Show full text]
  • Reversal of Neuromuscular Bl.Pdf
    JosephJoseph F.F. Answine,Answine, MDMD Staff Anesthesiologist Pinnacle Health Hospitals Harrisburg, PA Clinical Associate Professor of Anesthesiology Pennsylvania State University Hospital ReversalReversal ofof NeuromuscularNeuromuscular BlockadeBlockade DefiniDefinitionstions z ED95 - dose required to produce 95% suppression of the first twitch response. z 2xED95 – the ED95 multiplied by 2 / commonly used as the standard intubating dose for a NMBA. z T1 and T4 – first and fourth twitch heights (usually given as a % of the original twitch height). z Onset Time – end of injection of the NMBA to 95% T1 suppression. z Recovery Time – time from induction to 25% recovery of T1 (NMBAs are readily reversed with acetylcholinesterase inhibitors at this point). z Recovery Index – time from 25% to 75% T1. PharmacokineticsPharmacokinetics andand PharmacodynamicsPharmacodynamics z What is Pharmacokinetics? z The process by which a drug is absorbed, distributed, metabolized and eliminated by the body. z What is Pharmacodynamics? z The study of the action or effects of a drug on living organisms. Or, it is the study of the biochemical and physiological effects of drugs. For example; rocuronium reversibly binds to the post synaptic endplate, thereby, inhibiting the binding of acetylcholine. StructuralStructural ClassesClasses ofof NondepolarizingNondepolarizing RelaxantsRelaxants z Steroids: rocuronium bromide, vecuronium bromide, pancuronium bromide, pipecuronium bromide. z Benzylisoquinoliniums: atracurium besylate, mivacurium chloride, doxacurium chloride, cisatracurium besylate z Isoquinolones: curare, metocurine OnsetOnset ofof paralysisparalysis isis affectedaffected by:by: z Dose (relative to ED95) z Potency (number of molecules) z KEO (plasma equilibrium constant - chemistry/blood flow) — determined by factors that modify access to the neuromuscular junction such as cardiac output, distance of the muscle from the heart, and muscle blood flow (pharmacokinetic variables).
    [Show full text]